Danatlas Angel Round Financing
Time:2022-10-25
In March 2022, Beijing Danqing Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Danqing Pharmaceutical") recently announced the completion of tens of millions of yuan in angel round financing, which was exclusively invested by Mi Fang Health Fund.
Danqing Pharmaceutical is an innovation driven drug research and development company based in China and facing the world. It is committed to developing drugs targeting the "world's first (FIC)" targets in the era of tumor precision targeting 2.0, in order to meet the clinical needs of patients and promote medical innovation.
Danqing Pharmaceutical is headquartered in Beijing, China and has a branch center in Boston, USA. Founded by national level returnee scientists, the founding team has rich practical experience in new drug creation and R&D management, leading multiple innovative drugs with global influence to market. 85% of its core R&D team holds a master's degree or above and has made outstanding and sustained contributions in the development of cancer drugs.
The company has a 3000 square meter international first-class R&D laboratory, aiming to create a unique new drug development system and multidisciplinary integration technology platform, including the DQDD drug discovery platform that combines structural biology, computational chemistry, medicinal chemistry, and bioinformatics, and is equipped with a specialized operational support department. There are currently 5 global first in class new drug projects under development, and multiple PCT international invention patents have been applied for.
Founder Dr. Zhou Wenlai completed his postdoctoral research at the University of California, San Diego and subsequently led the development of innovative cancer drugs at Novartis Pharmaceuticals; From 2015 to 2021, as the Chief Biologist and Senior Management Officer of Jiakesi Pharmaceutical, I planned and supervised the implementation of the company's overall development strategy, pipeline layout, strategic cooperation, and other related work; And participate in leading the SHP2 project and collaborating globally with Abbvie in the United States for development. This is a representative case of China's small molecule innovative drugs entering the international stage, and also one of the largest transactions in terms of external authorization amount.
Dr. Zhou Wenlai, founder and chairman of Danqing Pharmaceutical, said: "Danqing is very honored to receive recognition and support from the Mi Fang Health Fund, which will help Danqing accelerate the preclinical research of multiple new target drugs with international competitiveness, and further build a target discovery and validation and DQDD drug discovery platform with Danqing's unique technological advantages. The joy of life lies in creation, and the meaning of creation lies in bringing extraordinary value to humanity. Danqing will adhere to the research and development philosophy of "sincerity and sincerity, with a focus on innovative medicine, we will regard human health", and make new contributions to the internationalization of Chinese innovative drugs.
As the exclusive investor in this round of financing, Mr. Hu Hongdan, Executive Director of Mi Fang Health Fund, stated: "Dr. Zhou Wenlai, the founder of Danqing Pharmaceutical, is a highly experienced scientist in the field of new drug research and development, with rich experience in successful research and development. Other core teams have also gone through the process of new drug research and development from 0 to 1. Starting from unmet clinical needs in the company's pipeline, we develop tumor targeted FIC drugs and promote multiple new target drugs with international competitiveness.
